Pressroom
NIH Awards $7.8 Million for Innovative HIV Vaccine Approaches
Source: NIH News
08/21/2012
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $7.8 million in first-year funding for basic research on new approaches to designing a safe and effective HIV vaccine. “Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development,” said Dr. Anthony S. Fauci, director of NIAID. “These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection.” NIAID awarded 14 grants under the Innovation for HIV Vaccine Discovery Initiative, and the recipient organizations include Harvard Medical School, which will receive $846,896 for fiscal year 2012 for its project “Natural Killer T Cells as Modulators of AIDS Vaccine Efficacy.” The University of Minnesota will receive $843,856 for its project “Vaccine Design to Concentrate Protective Antibodies at the Mucosal Border.” The University of Maryland-Baltimore will receive $779,175 for research on a “Neonatal Fc-Receptor-Targeted Mucosal HIV Vaccine.” The other grant recipients include Altravax; Catholic University of America; Dartmouth College; Duke University; Massachusetts General Hospital; NYU Langone Medical Center; University of California-Irvine; University of Medicine and Dentistry of New Jersey; University of North Carolina-Chapel Hill; University of Rochester; and University of Texas at El Paso.
